Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 14, 2008 Brian Lawler	Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
The Motley Fool July 12, 2007 Brian Lawler	Is It Time to Buy Genentech Yet? Genentech announces positive second-quarter results, but investors remain worried.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool January 11, 2006 Stephen D. Simpson	More Big, Boring Growth at Genentech The stock is expensive, and some may worry that Genentech didn't exceed estimates by as much as in the past.
The Motley Fool July 21, 2008 Brian Lawler	Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own.
The Motley Fool July 15, 2008 Brian Lawler	Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings?
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
The Motley Fool April 12, 2004 Charly Travers	Bargain Hunting in Big Biotech MedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors.
The Motley Fool October 22, 2010 Anand Chokkavelu	7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential.
The Motley Fool January 11, 2005 W.D. Crotty	Genentech's Pricey DNA The company continues to churn out sales and earnings gains, but it looks richly priced.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool January 25, 2007 Charly Travers	The Best Drug Stock for 2007 Is ... Is anyone surprised that the largest biotech company in the world, Genentech, came out on top?
The Motley Fool October 11, 2005 Stephen D. Simpson	Genentech Generates Profits Whether you call it a biotech or a pharmaceutical, there's no disputing that Genentech is raking in some big bucks. Trying to value this stock is no treat, but growth-oriented investors should still have much to look forward to over the years.
The Motley Fool January 5, 2004 Alyce Lomax	Side Effects at Lilly? Growing profits, with earnings pains.
The Motley Fool July 9, 2007 Rich Smith	Before the Call: Gauging Genentech Investors, don't focus on just this quarter. What's the big picture look like for the drug maker? Many investors seem willing to wait around for this stock.
The Motley Fool July 12, 2006 Stephen D. Simpson	Genentech's Deceptive Disappointment A slight shortfall in one product's sales is not a valid cause for panic. However, investors' patience might be wearing a bit thin here. What's more, Genentech's neither cheap nor undiscovered.
The Motley Fool June 16, 2004	Understanding "Multiples" Understanding multiples can help you evaluate a stock's attractiveness.
BusinessWeek January 12, 2004	Arthur Levinson The scientist-turned-CEO plans to move Genentech into the pharmaceutical big leagues.
The Motley Fool November 23, 2004 Charly Travers	Don't Be Afraid of Biotech You don't need to be a scientist to invest in this high-growth sector.
The Motley Fool January 19, 2007 Stephen Albainy-Jenei	The Best Drug Stock for 2007: Genentech Now that growth is starting to level off for Genentech's four main oncology drugs, many analysts have lowered their ratings and cooled on Genentech's future. But the company is more than just a list of drugs.
The Motley Fool December 12, 2005 Shannon Zimmerman	Genentech: Good Company, Bad Investment Stock valuations in the biotech industry are expensive in general, but on a trailing-12-month basis, Genentech's price-to-earnings, price-to-book, price-to-sales, and price-to-cash flow figures all dwarf those of the broader market. If the price isn't right, buyer beware.
The Motley Fool February 25, 2009 Brian Orelli	Will It Ever End? Genentech's Special Committee of its Board of Directors recommended that investors reject Roche's most recent tender offer.
The Motley Fool July 8, 2004 Charly Travers	Genentech's Next Billion-Dollar Drug The cancer drug Avastin looks like a big winner. The market had exceptionally high expectations for this product, and it certainly seems well on its way to becoming a blockbuster drug.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool July 8, 2004 Roger Nusbaum	Has Alcoa Reached Its Peak? While the price of aluminum soars, earnings reports for Alcoa, the world's largest aluminum company, are coming up short.
The Motley Fool January 15, 2008 Brian Lawler	Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool March 23, 2004 W.D. Crotty	Down on Drug News? An FDA advisory on labeling antidepressants shouldn't depress drug stocks.
The Motley Fool October 16, 2007 Brian Lawler	Genentech Fitting Better Cancer treatment Avastin continues to surge for the biopharma with a jump on the competition. Investors, take note.
The Motley Fool January 21, 2009 Brian Orelli	A Copycat on the Prowl Teva Pharmaceutical announces it is partnering with Lonza to develop generic versions of biologics, called biosimilars, or follow-on biologics.
The Motley Fool July 9, 2004 Charly Travers	Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL.
The Motley Fool April 8, 2004 Brian Gorman	Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs.
The Motley Fool July 20, 2005 Stephen D. Simpson	Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool April 12, 2004 Seth Jayson	Gannett's Ad-vantageous Q1 First-quarter earnings for Gannett, publisher of USA Today and hundreds of other newspapers, show strong increases in advertising revenues across every segment of the company.
The Motley Fool April 12, 2006 Stephen D. Simpson	Genentech Is Weird Genentech is undoubtedly a great biotech, but it seems like Wall Street obsesses about the wrong things. Investors, take note.
BusinessWeek December 13, 2004 Gene G. Marcial	Rich Suitors May Come Courting Curis With Genentech, Johnson & Johnson, and Wyeth as its partners, tiny Curis is a "sitting duck" for a takeover as it develops drugs to combat a number of diseases. One hedge-fund manager puts Curis' buyout value at $9 a share.
The Motley Fool July 26, 2011 Becca Lipman	Investing 101: 10 Rallying Yet Deeply Undervalued Companies Do you think the value of these companies will continue to rise?
The Motley Fool June 21, 2004 Seth Jayson	Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore.
The Motley Fool April 30, 2008 Brian Lawler	A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan.
The Motley Fool April 19, 2004 Seth Jayson	Lexmark Inks More Profits The printer maker lives up to its buzz and continues to increase earnings.
The Motley Fool March 11, 2004 Ben McClure	Quality Earnings Count Here are three telltale signs of strong earnings. This reporting period, it's worthwhile taking a peek behind the earnings. Here are three telltale signs of earnings "quality" to guide your stock picks.
The Motley Fool February 13, 2004 Matt Richey	Two With Hidden Value The price-to-earnings ratio can obscure a stock's true value. One of the most common "hiding places" for value is among companies that look fully valued on a P/E basis, but where the underlying business trades for a much cheaper multiple.
The Motley Fool August 14, 2008 Brian Lawler	Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid.
The Motley Fool February 27, 2004 Mark Mahorney	Shuffle Master's No Shell Game Gaming equipment company Shuffle Master had a big week, announcing two acquisitions and reporting fiscal first-quarter earnings.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool January 27, 2004 Rich Smith	American Standard Still Clogged American Standard reported strong results, but debt remains a factor.